# Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

> **NCT07629635** · PHASE3 · RECRUITING · sponsor: **Columbia University** · enrollment: 32 (estimated)

## Conditions studied

- Migraine Disease
- Patent Foramen Ovale

## Interventions

- **DRUG:** Prasugrel 5mg
- **DEVICE:** Transcatheter Closure of Patent Foramen Ovale

## Key facts

- **NCT ID:** NCT07629635
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629635, "Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*